GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Kanghua Biological Products Co Ltd (SZSE:300841) » Definitions » Purchase Of Investment

Chengdu Kanghua Biological Products Co (SZSE:300841) Purchase Of Investment : ¥-100 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Chengdu Kanghua Biological Products Co Purchase Of Investment?

Chengdu Kanghua Biological Products Co's purchase of investment for the three months ended in Mar. 2024 was ¥-100 Mil. It means Chengdu Kanghua Biological Products Co spent ¥100 Mil on purchasing investments. Chengdu Kanghua Biological Products Co's purchase of investment for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-100 Mil.

Compared with last quarter (¥0 Mil in Dec. 2023 ), Chengdu Kanghua Biological Products Co spent more money on purchasing investments in Mar. 2024 (¥-100 Mil).


Chengdu Kanghua Biological Products Co Purchase Of Investment Historical Data

The historical data trend for Chengdu Kanghua Biological Products Co's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Kanghua Biological Products Co Purchase Of Investment Chart

Chengdu Kanghua Biological Products Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only - -592.50 -850.25 -210.00 -56.50

Chengdu Kanghua Biological Products Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -100.00

Chengdu Kanghua Biological Products Co Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-100 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chengdu Kanghua Biological Products Co Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Chengdu Kanghua Biological Products Co's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Chengdu Kanghua Biological Products Co (SZSE:300841) Business Description

Traded in Other Exchanges
N/A
Address
No. 182, Beijing Road, Chengdu Economic and Technological Development Zone, Sichuan Province, Chengdu, CHN, 610100
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
Executives
Sun Wan Feng Executives
Hou Wen Li Directors, executives
Wu Wen Nian Executives
Chen Huai Gong Executives
Li Sheng You Executives
Wang Qing Han Directors, executives
Li Xiao Wen Supervisors

Chengdu Kanghua Biological Products Co (SZSE:300841) Headlines

No Headlines